Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD7503 in NAFLD and NASH
NCT05560607Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Primary completion
- Nov 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AZD7503 in non-alcoholic fatty liver disease (NAFLD) and Nonalcoholic steatohepatitis (NASH), sponsored by AstraZeneca. Primary endpoint: Number of participants with Adverse Events at 99 days. Started Aug 2022; status: completed.
02
Drugs
AZD7503
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05560607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560607.